Skip to main content
PolicySpeak
← All files
MUM

MUMC+

Academic / research · Netherlands

2
positions filed
in the 326 files tracked
1
legislative file
of 326 tracked
0
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Track MUMC+ in PolicySpeak: request access →

Work at MUMC+? so we know who speaks for it.

Follow the file MUMC+ engages with

One email on Tuesdays when a new position is filed on this file, from MUMC+ or from anyone else on it. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

MUMC+ filed 2 positions between 18 Sept 2025 and 13 Feb 2026, across 1 of the 326 legislative files tracked here.

2025 · 1 filed2026 · 1 filed

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 13 Feb 2026source

The proposed relaxations within the IVDR legislation can have a positive impact on the development, implementation and application of LDTs within diagnostics. The increased flexibility and simplified procedures contribute to a more efficient use of clinical trials, which can ultimately lead to better patient care and innovation in medical diagnostics. 1.

Filed in Dutch · English published by the European Commission

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 18 Sept 2025source

1. Properly functioning CE labelled tests are taken out of production, as it is costly for manufacturers to comply with the CE IVD standard. This reduces the quality of diagnostics because alternatives are less of quality or do not exist at all. This cannot be the intention. 2. Exchange of LDTs in the absence of a CE IVD alternative (e.g. rare diseases or multicer studies) is not possible under current legislation.

Filed in Dutch · English published by the European Commission

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Is this your organization?

Everything on this page comes from MUMC+’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.